Brainstorm Cell Therapeutics Inc. SEC filings BCLI

Brainstorm Cell Therapeutics Inc. has 949 filings in SEC EDGAR's recent list, going back to May 24, 2001. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 14, 2026 (results of operations). The company's fiscal year ends on December 31.

Brainstorm Cell Therapeutics Inc. SEC filings
Form Description Filed Period
10-Q Quarterly report Aug 14, 2026 Jun 30, 2026
10-Q Quarterly report May 15, 2026 Mar 31, 2026
10-Q Quarterly report Nov 14, 2025 Sep 30, 2025
10-Q Quarterly report Aug 14, 2025 Jun 30, 2025
10-Q Quarterly report May 15, 2025 Mar 31, 2025
10-Q Quarterly report Nov 14, 2024 Sep 30, 2024
10-Q Quarterly report Aug 14, 2024 Jun 30, 2024
10-Q Quarterly report May 14, 2024 Mar 31, 2024
10-Q Quarterly report Nov 14, 2023 Sep 30, 2023
10-Q Quarterly report Aug 14, 2023 Jun 30, 2023
10-Q Quarterly report May 15, 2023 Mar 31, 2023
10-Q Quarterly report Nov 14, 2022 Sep 30, 2022
10-Q Quarterly report Aug 15, 2022 Jun 30, 2022
10-Q Quarterly report May 16, 2022 Mar 31, 2022
10-Q Quarterly report Nov 15, 2021 Sep 30, 2021
10-Q Quarterly report Aug 5, 2021 Jun 30, 2021
10-Q Quarterly report Apr 26, 2021 Mar 31, 2021
10-Q Quarterly report Oct 15, 2020 Sep 30, 2020
10-Q Quarterly report Aug 5, 2020 Jun 30, 2020
10-Q Quarterly report May 7, 2020 Mar 31, 2020
10-Q Quarterly report Nov 14, 2019 Sep 30, 2019
10-Q Quarterly report Aug 13, 2019 Jun 30, 2019
10-Q Quarterly report May 10, 2019 Mar 31, 2019
10-Q Quarterly report Oct 29, 2018 Sep 30, 2018
10-Q Quarterly report Jul 23, 2018 Jun 30, 2018
10-Q Quarterly report May 14, 2018 Mar 31, 2018
10-Q Quarterly report Oct 17, 2017 Sep 30, 2017
10-Q Quarterly report Aug 14, 2017 Jun 30, 2017
10-Q Quarterly report May 15, 2017 Mar 31, 2017
10-Q Quarterly report Nov 14, 2016 Sep 30, 2016
10-Q Quarterly report Aug 11, 2016 Jun 30, 2016
10-Q Quarterly report May 10, 2016 Mar 31, 2016
10-Q Quarterly report Nov 16, 2015 Sep 30, 2015
10-Q Quarterly report Aug 13, 2015 Jun 30, 2015
10-Q Quarterly report May 14, 2015 Mar 31, 2015
10-Q Quarterly report Nov 13, 2014 Sep 30, 2014
10-Q Quarterly report Aug 12, 2014 Jun 30, 2014
10-Q Quarterly report May 13, 2014 Mar 31, 2014
10-Q Quarterly report Nov 14, 2013 Sep 30, 2013
10-Q Quarterly report Aug 14, 2013 Jun 30, 2013
10-Q Quarterly report May 9, 2013 Mar 31, 2013
10-Q Quarterly report Nov 13, 2012 Sep 30, 2012
10-Q/A Amended quarterly report Aug 29, 2012 Jun 30, 2012
10-Q Quarterly report Aug 13, 2012 Jun 30, 2012
10-Q Quarterly report May 11, 2012 Mar 31, 2012
10-Q Quarterly report Nov 14, 2011 Sep 30, 2011
10-Q/A Amended quarterly report Sep 7, 2011 Jun 30, 2011
10-Q Quarterly report Aug 15, 2011 Jun 30, 2011
10-Q Quarterly report May 13, 2011 Mar 31, 2011
10-Q Quarterly report Nov 15, 2010 Sep 30, 2010
10-Q Quarterly report Aug 16, 2010 Jun 30, 2010
10-Q Quarterly report May 17, 2010 Mar 31, 2010
10-Q Quarterly report Nov 16, 2009 Sep 30, 2009
10-Q Quarterly report Aug 19, 2009 Jun 30, 2009
10-Q Quarterly report May 14, 2009 Mar 31, 2009
10-Q Quarterly report Nov 19, 2008 Sep 30, 2008
10-Q Quarterly report Aug 13, 2008 Jun 30, 2008
10-Q Quarterly report May 15, 2008 Mar 31, 2008

Showing 58 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
BCLI (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1137883
Former names
BRAINSTORM CELL THERAPEUTICS INC (until Jul 23, 2012); GOLDEN HAND RESOURCES INC (until Nov 22, 2004); WIZBANG TECHNOLOGIES INC (until Aug 8, 2003)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.